Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 10 Show results per page	View Search Criteria \| Help With Results

Last Modified: 12/1/1998


1.		Phase II Study of Melphalan (L-PAM) Plus Buthionine Sulfoximine (BSO) in Patients with Metastatic Melanoma (Summary Last Modified 12/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				MCGILL-T93-0176 NCI-T93-0176O, T93-0176

Last Modified: 12/1/2000


2.		Phase II Study of BSO/L-PAM in Relapsed or Refractory Ovarian Cancer (Summary Last Modified 12/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				over 18				NCI				FCCC-95126 NCI-T95-0008D, T95-0008

Last Modified: 2/1/2002


3.		Phase I Pilot Study of BSO/L-PAM for High-Risk Pediatric Neuroblastoma (Summary Last Modified 02/2002)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				No greater than 21 at diagnosis				NCI				CHLA-95-083 NCI-T95-0092O, NCT00002730, T95-0092

Last Modified: 8/22/2006


4.		Phase I Study of Buthionine Sulfoximine in Recurrent Acute Myeloblastic Leukemia (Summary Last Modified 05/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				No age specified				NCI				CAN-OCI-97-01-AML01 NCI-T96-0107, T96-0107

Last Modified: 5/1/1992


5.		Phase I Clinical and Pharmacokinetic Investigation of Intravenous Buthionine Sulfoximine/Melphalan in Patients with Refractory Advanced Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 and over				NCI				OSU-89HO204 NCI-T89-0124C, T89-0124

Last Modified: 6/1/1993


6.		Phase I Study of Buthionine Sulfoximine with Melphalan in Patients with Solid Tumors or Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				over 18				NCI				FCCC-88035 NCI-T88-0242D, T88-0242

Last Modified: 1/1/1992


7.		Phase I Study of Modulation of Glutathione Chemoprotection with Intravenous BSO in Patients Receiving L-PAM for Advanced Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				at least 18				NCI				WCCC-CO-8897 NCI-T88-0189C, T88-0189

Last Modified: 11/15/2007


8.		Phase I Study of L-PAM/BSO in Patients with Hematologic Malignancies Other Than Acute Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over				NCI				UCCRC-6000 NCI-T90-0175C, T90-0175

Last Modified: 11/1/1999


9.		Phase I Study of Once-Daily BSO in Patients Receiving Localized Radiotherapy (Summary Last Modified 11/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over				NCI				MCGILL-ET-9014 NCI-T90-0198O, T90-0198

Last Modified: 12/1/1993


10.		Phase I Study of Intravenous BSO, Administered as an Initial Bolus Followed by a 24- to 48-Hour Continuous Infusion, Given with Intravenous L-PAM in Patients with Advanced Malignancies Including Melanoma and Ovarian Epithelial Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over				NCI				WCCC-CO-9296 NCI-T92-0206D, T92-0206

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute